{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007740","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.160984+00:00","generated_at":"2026-05-21T08:52:23.217678+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MetaVia reports Q1 net loss $3.7M; DA-1726 shows 4.3% mean weight loss in Phase 1","bullets":["Cash $11.2M at Q1-end; plus $10M private placement in May, funding into 2026.","Net loss $3.7M ($0.36/sh) vs $6.7M ($1.32/sh) YoY; R&D spend down to $2.3M from $4.9M.","DA-1726 (obesity) mean weight loss 4.3% at 32 mg at Day 26 (p=0.0005); max 6.3%; no titration needed.","DA-1241 (MASH) Phase 2a reduced ALT 22.8 U/L at 16 weeks; end-of-Phase 2 FDA meeting expected H1 2025.","Additional DA-1726 dose cohorts to start Q3 2025; data expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007740","json":"https://secwatch.observer/filing/0001558370-25-007740.json","markdown":"https://secwatch.observer/filing/0001558370-25-007740.md","text":"https://secwatch.observer/filing/0001558370-25-007740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025007740/0001558370-25-007740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025007740/mtva-20250514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:52:23.217678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}